Dr. Pradeep Kumar Thapa 
MBBS, DNB
Nuclear Medicine Physician, Radiation Oncologist
Senior Consultant
16 Years of Experience
Aarvy Healthcare Super Speciality Hospital, Gurugram
English, Hindi
About Dr. Pradeep Kumar Thapa
Dr. Pradeep Kumar Thapa is a senior nuclear medicine specialist based in Gurugram, practicing at American Oncology Institute, with over a decade of expertise in diagnostic and therapeutic nuclear medicine. He combines cutting-edge imaging, radionuclide therapy, and personalized oncology care to manage complex cases involving thyroid, neuroendocrine, bone metastases, and prostate cancers.
His credentials include DRM in Radiation Medicine, DNB in Nuclear Medicine, and fellowship credentials from Europe, making him proficient in PET-CT / SPECT-CT modalities, radioisotope therapies such as Lutetium DOTANOC, I-131 therapy, and novel tracers like Ga-68 PSMA and Ga-68 DOTANOC.
Qualifications of Dr. Pradeep Kumar Thapa
- MBBS
- DRM (Radiation Medicine / Nuclear Medicine)
- DNB (Nuclear Medicine)
- Fellowship (European Board of Nuclear Medicine)
Special Area of Interest
- PET-CT imaging & interpretation
- SPECT-CT & gamma camera studies
- Radionuclide therapy: Lutetium DOTANOC, ^177Lu-PSMA, I-131, Sm-153, ^131I-MIBG
- Thyroid cancer diagnosis & radioiodine therapy
- Bone pain palliation in skeletal metastases
- Neuroendocrine tumor management
- New tracer development and theranostics
Work Experience of Dr. Pradeep Kumar Thapa
- Consultant, Nuclear Medicine – Basavatarakam Indo-American Cancer Hospital & Research Institute, Hyderabad (Dec 2022 – May 2024)
- Consultant, Nuclear Medicine – Venkateshwar Hospital, Dwarka, New Delhi (Jun 2016 – Dec 2022)
- Consultant, Nuclear Medicine – Vijaya Diagnostic Centre, Hyderabad (Aug 2015 – Jun 2016)
- PET-CT Fellowship, Medanta Hospital, Gurgaon (Jul 2015 – Aug 2015)
- Senior Resident, Nuclear Medicine, Safdarjung Hospital, New Delhi (Jun 2012 – Feb 2013)
Awards & Recognitions
- Alavi-Mandell Award for publication on comparative efficacy of ^177Lu-EDTMP vs ^153Sm-EDTMP in painful bone metastases
- Best Poster Award: “Comparative study between Tc-99m Methionine and C-11 Methionine in recurrence of brain tumors” at SNM India conference 2011
Memberships
- Member, European Association of Nuclear Medicine
- Member, Society of Nuclear Medicine, India
Research & Papers Published By Dr. Pradeep Kumar Thapa
- Thapa P, Basu S. Leveraging non-radium radionuclide therapies in bone metastases
- Basu S et al., Thapa P. Peptide receptor radionuclide therapy with indigenous ^177Lu-DOTATATE
- Thapa P, Kalshetty A, Basu S. ^18F-FDG PET/CT in carcinoma of unknown primary
- Dutta D et al., Thapa P. Occult phosphaturic mesenchymal tumour causing oncogenic osteomalacia
- Thapa P, Parghane R, Basu S. ^177Lu DOTATATE therapy in metastatic / inoperable neuroendocrine tumors
Dr. Pradeep Kumar Thapa
MBBS, DNB Nuclear Medicine Physician, Radiation Oncologist16 Years of Experience
Dr. Ishita Barat Sen
MBBS, DNB Nuclear Medicine Physician, Radiation Oncologist16 Years of Experience
Frequently Asked Questions
He uses PET-CT, SPECT-CT, gamma camera imaging, and advanced tracer scans (Ga-68 DOTANOC, Ga-68 PSMA).
^177Lu DOTANOC for neuroendocrine tumors, ^177Lu PSMA for prostate cancer, I-131 for thyroid malignancies, Sm-153 / ^177Lu-EDTMP for bone palliation and ^131I-MIBG for neuroblastoma / paraganglioma.
He has authored papers on radionuclide therapy in bone metastases, PET/CT use in unknown primaries, and therapy in neuroendocrine tumors among others.
He has held consultant roles in Hyderabad, Delhi (Venkateshwar Hospital), and diagnostic centers, and also served as Senior Resident in New Delhi
He specializes in radionuclide imaging and therapy (theranostics), thyroid cancer care, neuroendocrine tumor therapies, and metastatic cancer management.
